Neuropeptide S

What is Neuropeptide S?

Neuropeptide S (NPS) is a 20-amino-acid endogenous neuropeptide whose name records its single most distinctive structural feature — the highly conserved N-terminal serine residue that begins the mature peptide and that is absolutely required for receptor activation. The human mature peptide is Ser-Phe-Arg-Asn-Gly-Val-Gly-Thr-Gly-Met-Lys-Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser (UniProt P0C0P6, residues 70–89); the rat sequence differs at six positions (SFRNGVGSGVKKTSFRRAKQ) and is frequently reproduced as if it were the human form, since most of the founding pharmacology was done in rat. NPS was discovered by Yan-Ling Xu, Rainer Reinscheid, Olivier Civelli, and colleagues at the University of California Irvine in 2004 (Neuron) using a reverse-pharmacology approach: the orphan G-protein-coupled receptor GPR154 (also known as GPRA, VRR1, and now formally NPSR1) had been linked to asthma susceptibility by Tarja Laitinen, Juha Kere, and colleagues in a 2004 Science paper, and the Civelli group screened a peptide library on GPR154-expressing cells to identify the endogenous ligand. The result was a novel peptide encoded by a previously uncharacterized precursor gene (NPS, on human chromosome 10q26), processed to the mature 20-residue active form. NPSR1 is a Gs- and Gq-coupled receptor that elevates intracellular cAMP and mobilizes calcium, with expression concentrated in the amygdala, cortex, hypothalamus, midbrain, and brainstem — anatomical regions consistent with NPS's striking dual phenotype: central administration in rodents simultaneously increases wakefulness and arousal AND produces anxiolytic-like behavior, a pharmacological combination that classical anxiolytics (which sedate) do not deliver. The 2019 Sci Transl Med paper by Lijuan Xing, Guangsen Shi, Louis Ptáček, Ying-Hui Fu and colleagues identified a single NPSR1 missense mutation — Tyr206His — that produces a familial natural short-sleeper phenotype — humans who require ~6 hours of sleep without measurable cognitive or health consequences — establishing NPSR1 as a genuine human sleep-regulator. NPSR1 polymorphisms are also associated with panic disorder susceptibility and with childhood asthma, the latter reflecting peripheral NPSR1 expression in airway epithelium and immune cells. Drug development around NPSR1 has produced research-grade selective antagonists (notably SHA 68) used as tool compounds for anxiety, addiction, and PTSD pharmacology — but no NPS or NPSR1 product has reached approval for any indication.

What Neuropeptide S Is Investigated For

NPS is an endogenous-biology and drug-target topic, not a peptide consumers take. Its scientific footprint covers four overlapping areas. First, the dual arousal-plus-anxiolysis pharmacology established by the founding 2004 Neuron paper — central NPS administration in rodents increases wakefulness and arousal while simultaneously reducing anxiety-like behavior in standard paradigms (elevated plus maze, open field, defensive burying), a combination that classical anxiolytics like benzodiazepines do not produce because they trade anxiolysis for sedation. Second, the human sleep genetics: the 2019 Xing et al. Sci Transl Med paper identified NPSR1 missense mutations in pedigrees of natural short sleepers — humans who need only about six hours of sleep without obvious cognitive or health consequences — formally establishing NPSR1 as a human sleep-duration regulator. Third, the panic-disorder and psychiatric genetics: NPSR1 polymorphisms (the Asn107Ile variant) have been associated with panic disorder susceptibility in independent cohorts (Domschke 2011 Mol Psychiatry; Okamura 2007 Prog Neuropsychopharmacol Biol Psychiatry), and rodent studies have implicated NPS in fear extinction (Jüngling 2008 Neuron) and stress-induced reinstatement of alcohol seeking (Cannella 2009 Neuropsychopharmacology). Fourth, the asthma genetics: NPSR1 (originally identified as GPRA in a 2004 Science asthma-genetics paper from the Laitinen and Kere groups) is associated with childhood and adult asthma in multiple cohorts, reflecting peripheral receptor expression in airway epithelium and immune cells — the original biological context of receptor identification before its CNS pharmacology was understood. The drug-development chapter has been slow: selective NPSR1 antagonists (SHA 68 and successor compounds) and the conformation-activity-relationship pharmacology of NPS analogues (Tancredi 2007 J Med Chem) are research-grade tools, but no NPS or NPSR1 ligand has reached approval for any anxiety, addiction, sleep, or asthma indication.

History & Discovery

NPS was discovered through one of the cleaner reverse-pharmacology stories in modern peptide biology. The orphan G-protein-coupled receptor GPR154 (also called GPRA, VRR1) had been identified by Tarja Laitinen, Juha Kere, and colleagues in Helsinki — the lead affiliation on the paper is the biotechnology company GeneOS Ltd rather than the university — through positional cloning across three cohorts from Finland and Canada, and reported in Science in March 2004 as a susceptibility locus for asthma and atopy — at that point the receptor was an orphan with a clear human disease-genetics signal but no known ligand. Yan-Ling Xu, Rainer Reinscheid, Olivier Civelli, and colleagues at the University of California Irvine took up the deorphanization, screened a peptide library against GPR154-expressing cells, and identified the endogenous ligand: a previously uncharacterized 20-amino-acid peptide encoded by a single-copy gene that they named neuropeptide S after the conserved N-terminal serine. The August 2004 Neuron paper reported the discovery, the structure-activity relationship of NPS at GPR154, and the striking dual pharmacological profile — central NPS administration in rats simultaneously increased wakefulness and arousal AND reduced anxiety-like behavior. The combination is unusual: classical anxiolytics like benzodiazepines trade anxiolysis for sedation, and classical arousal-promoting agents like caffeine often increase anxiety. NPS does both at once. The human-genetics chapter expanded over the following decade and a half. The Asn107Ile NPSR1 polymorphism was associated with panic disorder susceptibility in multiple cohorts (Domschke 2011 Mol Psychiatry; Okamura 2007 PNPBP). Asthma genetics confirmed the original GPRA/NPSR1 association in Italian, Canadian, and other populations. In 2019, Lijuan Xing, Guangsen Shi, Louis Ptáček, and Ying-Hui Fu published the Sci Transl Med paper that identified the NPSR1 Tyr206His missense mutation in pedigrees of natural short sleepers — individuals with a heritable, lifelong, asymptomatic six-hour-per-night sleep requirement — and confirmed the phenotype in knock-in mice. NPSR1 joined the small set of validated human sleep-need genes, which by 2026 comprises DEC2 (BHLHE41), NPSR1, ADRB1, GRM1 and SIK3. Drug discovery has produced research-grade selective NPSR1 antagonists, most notably SHA 68 (Okamura, Reinscheid, and colleagues 2008), used as a tool compound in fear-extinction, anxiety, and addiction studies. As of 2026 no NPSR1 ligand has reached registered clinical development at all — there is no interventional trial of NPS or any NPSR1 modulator on ClinicalTrials.gov, and no experimental structure of the receptor has been solved. NPS and NPSR1 remain a credible drug-discovery target with strong validation across human genetics and rodent pharmacology, but the clinical chapter has not begun, let alone been written.

How It Works

Neuropeptide S is a 20-amino-acid signaling protein your brain makes that does something most other peptides cannot: it wakes you up and calms anxiety at the same time. In animal experiments, injecting NPS into the brain makes the animal more alert, exploratory, and curious — but also less anxious in the kinds of behavioral tests scientists use to measure fear. That combination is unusual: most anxiety-reducing drugs (like Xanax or Ativan) also make you sleepy, and most arousal-promoting drugs (like caffeine) often increase anxiety. NPS pulls off both effects through a single receptor called NPSR1. Rare humans who carry a mutation in this receptor are 'natural short sleepers' — they only need about six hours of sleep with no apparent downside. Different mutations in the same receptor are linked to panic disorder and asthma, which makes NPSR1 one of the more interesting drug targets in psychiatry and respiratory medicine — though no NPS-targeted drug has yet reached approval.

Neuropeptide S is a 20-amino-acid peptide encoded by the NPS gene on human chromosome 10q26 and processed from a 89-residue precursor (preproNPS) by signal-peptide cleavage and a single proteolytic step. The mature peptide begins with the conserved Ser-Phe-Arg-Asn (SFRN) N-terminal motif that gives NPS its name and its absolute requirement for receptor activation; substitutions or N-terminal truncations abolish bioactivity. NPS is expressed by a small number of brainstem neuronal populations, most notably a cluster in the lateral parabrachial area near the locus coeruleus, with axonal projections to widespread forebrain targets including the amygdala, hypothalamus, paraventricular thalamus, and cortex. NPS signals through NPSR1 (the gene previously called GPR154, GPRA, or VRR1), a class-A rhodopsin-family GPCR with low-nanomolar affinity for NPS. NPSR1 couples to both Gs (elevating cAMP through adenylate cyclase activation) and Gq (mobilizing intracellular calcium through phospholipase C and IP3 signaling) — a dual coupling that is unusual among monoaminergic-target G-proteins and that may underlie NPS's behaviorally distinctive arousal-plus-anxiolysis combination. The receptor carries a common functional coding polymorphism at position 107 in the first extracellular loop, producing two isoforms: Asn107 and Ile107. The direction matters and is often reported backwards — Ile107 is the gain-of-function allele, with roughly tenfold greater agonist sensitivity, and the mechanism is an increase in agonist potency with no change in binding affinity (Reinscheid 2005 J Pharmacol Exp Ther; Okamura 2007). The mouse receptor also carries Ile at position 107 and shows an intermediate profile. Both isoforms have been associated with psychiatric phenotypes including panic disorder susceptibility, though as noted in the research gaps the reported sex-specificity runs in opposite directions between the two anchor cohorts. NPSR1 is also expressed in airway epithelium, smooth muscle, and immune cells, and polymorphisms in the gene have been associated with childhood and adult asthma — the original genetic context in which the receptor was identified before its central pharmacology was characterized (Laitinen 2004 Science; Malerba 2007 Clin Exp Allergy). Functionally, central NPS administration in rodents produces a striking dual phenotype. Arousal: increased wakefulness, locomotor activation, and exploratory behavior. Anxiolysis: reduced freezing, reduced avoidance, and increased open-arm time in the elevated plus maze. Memory: enhanced consolidation in inhibitory-avoidance and novel-object-recognition paradigms, with the effect attenuated by the beta-blocker propranolol, implicating noradrenergic signaling (Okamura 2011 Neuropsychopharmacology). Caragea, Jüngling, and Méndez-Couz (Behav Brain Funct 2026) synthesized the human and animal literature in a systematic review and concluded that NPS modulates all phases of memory — acquisition, consolidation, retrieval, and extinction — enhancing spatial and object-memory consolidation and inhibitory-avoidance consolidation while interfering with working and short-term memory, with effects preferentially targeting emotionally or motivationally salient learning through interactions with orexinergic, dopaminergic, and noradrenergic systems. Fear extinction: NPS facilitates extinction of conditioned fear when administered into the amygdala, and the cellular mechanism is more specific than it is usually stated — NPS increases glutamatergic transmission onto intercalated GABAergic neurons via presynaptic NPS receptors located on the connected principal neurons, so the intercalated cells are the target of the effect rather than the NPSR-bearing cells themselves (Jüngling 2008 Neuron). The finding has translational relevance for PTSD. Reward and addiction: central NPS administration produces persistent increases in alcohol-seeking behavior in rats (Cannella 2009 Neuropsychopharmacology), with the effect mediated through hypothalamic hypocretin/orexin signaling — implicating NPS in the addiction-relevant arousal/motivation axis. Neuropathic pain: Patil and colleagues (Eur J Pharmacol 2026) extended the NPS–orexin coupling to a therapeutic axis, showing that intra-lateral-hypothalamic NPS injection raised paw-withdrawal latency and threshold in rats with chronic constriction injury while the NPSR antagonist SHA 68 worsened them. The circuit is more precisely localized than a simple shared-pathway account would suggest: orexin-1/2 receptor blockade in the ventrolateral periaqueductal gray abolished the effect, whereas infusions into the nucleus accumbens and ventral tegmental area produced only partial blockade — so this is not literally the same circuit Cannella implicated in alcohol seeking, but an overlapping lateral-hypothalamic orexinergic output. NPS modulation of pain and affective state was already known; what this work adds is the mechanism. The human-genetics chapter is dominated by two findings. The 2019 Xing, Shi, Ptáček, Fu Sci Transl Med paper identified a single NPSR1 missense mutation, Tyr206His, in human natural short sleepers — individuals with a heritable short-sleep phenotype. Knock-in mice carrying the human variant slept less than wild-type despite increased sleep pressure and were resistant to the contextual-memory deficits that normally follow sleep deprivation, formally establishing NPSR1 as a human sleep-duration regulator. It is important not to conflate Tyr206His with Asn107Ile: the latter is the common functional polymorphism associated with asthma and panic disorder, not a short-sleep mutation, and the two sit in different parts of the receptor with different consequences. The Laitinen 2004 Science paper had earlier identified GPRA (NPSR1) polymorphisms as asthma susceptibility variants in Finnish pedigrees, with subsequent confirmation in Italian and other cohorts. The dual psychiatric-and-respiratory genetics of a single receptor is unusual and reflects NPSR1's expression in distinct tissue compartments with distinct downstream consequences.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Neuropeptide S:

• 01Whether selective NPSR1 antagonists or agonists can deliver clinically meaningful efficacy in anxiety, panic disorder, PTSD, or alcohol use disorder — two decades of preclinical target validation has not produced an approved drug, and the directional question (agonism vs. antagonism) for each indication remains incompletely resolved.
• 02Whether NPS-pathway modulation could be exploited for sleep-disorder therapeutics, given the natural-short-sleeper genetics — and whether the dual arousal-plus-anxiolysis profile makes NPS-targeted insomnia therapy uniquely tolerable or uniquely problematic.
• 03The relative contribution of central versus peripheral NPSR1 signaling to disease phenotypes — particularly whether airway-restricted NPSR1 modulation could provide asthma therapeutics without CNS effects.
• 04The functional consequences of human NPSR1 polymorphisms at the receptor-pharmacology level are reasonably well established — Ile107 is gain-of-function with roughly tenfold greater agonist potency and unchanged binding affinity — but whether genotype-stratified clinical-trial designs would improve detection of NPS-pathway efficacy has never been tested.
• 05The panic-disorder association does not replicate in the same direction across cohorts, and the page's own anchor studies disagree: Okamura 2007 found the association in Japanese male patients, with the less-active Asn107 allele under-represented in males, while Domschke 2011 found the more-active rs324981 T allele associated with panic disorder in the female subgroup of a German cohort. These are opposite sex-specific effects for the same locus. Whether this reflects population structure, phenotype definition, or an unstable underlying association is unresolved, and it should temper the common summary that independent cohorts have converged.
• 06Whether NPS's enhancement of fear extinction in amygdala intercalated cells (Jüngling 2008) translates to PTSD therapeutic potential in humans, and whether NPS-pathway modulation could augment exposure-based therapy.
• 07Whether the newly-characterized NPS analgesic activity in rodent neuropathic-pain models (Patil 2026 Eur J Pharmacol, via lateral-hypothalamic orexinergic signaling) opens a chronic-pain indication for NPS-pathway modulators, and whether the mechanism is separable from the alcohol-seeking phenotype that Cannella 2009 documented through the same orexin coupling.
• 08Whether sex-hormone modulation of periLC NPS neurons (Laukamp 2026 Pflugers Arch showed estrous-cycle-dependent excitability changes) has translational implications for sex differences in the anxiety, arousal, and sleep phenotypes attributed to NPS signaling.
• 09The scope of peripheral NPSR1 signaling now extends well beyond airway epithelium, and the page's classical central-versus-respiratory framing is several indications out of date: NPSR1 drives chronic colitis through CD4+ T-cell effector function in inflammatory bowel disease (Peng 2024), NPSR1 polymorphisms have been examined in rheumatoid arthritis (D'Amato 2010), and Yu et al. 2026 identified NPSR1-positive malignant-cell populations in colorectal cancer liver metastases driven by neuromedin-B-secreting T cells. A coherent account of what NPSR1 does in immune and epithelial tissue, and whether it is pro-inflammatory across all of them, does not yet exist.
• 10Whether local NPS delivery has regenerative applications — a 2026 study embedded NPS in a pH-responsive self-healing hydrogel for controlled release after spinal cord injury in rats and reported neural repair mediated through the NPS-NPSR axis and downstream calcium and cAMP signaling. This is an entirely new delivery-and-indication axis for a peptide otherwise studied by central injection, and it is a single preclinical report.

Forms & Administration

NPS is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic NPS for in vitro NPSR1 binding and signaling assays, ex vivo brain-slice pharmacology, and intracerebroventricular or intranasal administration in animal models. SHA 68 and successor selective NPSR1 antagonists are research compounds. Compounded NPS from peptide marketplaces has no validated clinical use and no quality-controlled reference product.

Common Questions

Who Neuropeptide S Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for NPS because no NPS product has been clinically developed. Theoretical interactions follow from NPS's documented signaling. The arousal phenotype overlaps mechanistically with stimulants (caffeine, amphetamines, modafinil) and orexin/hypocretin-receptor pharmacology — NPS-induced alcohol-seeking is mediated through the hypothalamic hypocretin system (Cannella 2009), suggesting bidirectional cross-talk with orexin-receptor antagonists in development for insomnia (suvorexant, lemborexant, daridorexant). The anxiolytic phenotype could in principle interact with GABAergic anxiolytics, SSRIs, SNRIs, and benzodiazepines. NPSR1's peripheral expression in airway tissues raises theoretical interaction with asthma medications. None of these interactions has been characterized in controlled human studies; they are mechanistic possibilities that argue against casual exogenous NPS exposure rather than documented clinical events.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions